PDCD1 and neoplasm: By inhibiting the PD‐1/PDL‐1 signaling pathway with inhibitors such as nivolumab, pembrolizumab, durvalumab, and atezolizumab, which were administered in our immunotherapy subgroup, the T cells can recognize the tumor cells as pathogens and eliminate them.1, 2, 5, 7, 20